Form 4 for HOWL Werewolf Therapeutics, Inc.
Accepted 2026-05-20 18:08:29 ET · period of report 2026-05-18 · accession 0001134657-26-000012 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MTI | 2026-05-20 18:08 | 2026-05-18+ | HOWL | EVNIN LUKE | Dir | S - Sale | $0.4464 | -171.0K | 955.4K | -15% | -$76.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-18 | S | D | 22,184 | $0.5 | 1,104,312 | I See Footnotes | — | — | (F1) Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026. (F2) The shares were sold as follows: 2,377 by MPM Asset Management LLC ("AM LLC"), 15,006 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,001 by MPM BIoVentures 2014(B), L.P. ("BV 2014(B)"), 517 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 3,283 by MPM Oncology Innovations Fund, L.P. ("MPM OIF"). (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.4931 to $0.5059 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. (F4) MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. (F5) The shares are held as follows: 118,316 by AM LLC, 747,025 by BV 2014, 49,823 by BV 2014(B), 25,710 by AM BV2014 and 163,438 by MPM OIF. |
| 2 | Common | Common Stock | 2026-05-19 | S | D | 62,970 | $0.45 | 1,041,342 | I See Footnotes | — | — | (F1) Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026. (F6) The shares were sold as follows: 6,747 by AM LLC, 42,596 by BV 2014, 2,841 by BV 2014(B), 1,466 by AM BV2014 and 9,320 by MPM OIF. (F7) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.4243 to $0.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. (F4) MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. (F8) The shares are held as follows: 111,569 by AM LLC, 704,429 by BV 2014, 46,982 by BV 2014(B), 24,244 by AM BV2014 and 154,118 by MPM OIF. |
| 3 | Common | Common Stock | 2026-05-20 | S | D | 85,895 | $0.43 | 955,447 | I See Footnotes | — | — | (F1) Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026. (F9) The shares were sold as follows: 9,203 by AM LLC, 58,105 by BV 2014, 3,875 by BV 2014(B), 2,000 by AM BV2014 and 12,712 by MPM OIF. (F10) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.40905 to $0.4455 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. (F4) MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. (F11) The shares are held as follows: 102,366 by AM LLC, 646,324 by BV 2014, 43,107 by BV 2014(B), 22,244 by AM BV2014 and 141,406 by MPM OIF. |